In a pooled analysis with 57,531 unique patients, pCR-LN rates were reported in 60% of hormone receptor-negative/HER2-positive, 48% of TNBC, 45% of hormone receptor-positive/HER2-positive, 35% of luminal B, 18% of hormone receptor-positive/HER2-negative, and 13% of luminal A breast cancer. The gene discussed is NR4A1; the disease is breast carcinoma.